PDCD1 and hepatocellular carcinoma: As shown in Figure 4F, the IPS–PD1 blocker score, the IPS–CTLA4 score, and the PD1 blocker score in cluster 2 were significantly higher than those in cluster 1, which indicated a more immunogenic phenotype in cluster 2, so HCC patients in cluster 2 might benefit from immunotherapy.